When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

JPMorgan highlights valuation resets for Viking and Structure Therapeutics, citing opportunities in T2D/obesity and competitive clinical data insights.

With a 31.1% gain, 2024 has proven to be my most successful investing year. Read more to see what I expect from 2025.

Novo Nordisk is paying $55 million upfront to secure rights to a cell therapy for heart failure developed by Japanese startup Heartseed. The Danish drugmaker has acquired exclusive rights outside ...

Al Jazeera’s Moath al-Kahlout, one of the few journalists in northern Gaza, has been to the scene of an Israeli attack. Hamas tells news agencies it has approved a list of 34 captives to be ...

As Bulgaria joined Europe's borderless travel zone on January 1st, Greeks have been freely flocking to the neighboring country, where petrol prices are cheaper, to fill up their tanks. Bulgaria, along ...